Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
09/08/201814h00GlobeNewswire Inc.Portola Pharmaceuticals Appoints Ernie Meyer as Executive Vice President and Chief Human Resources OfficerNASDAQ:PTLAPortola Pharmaceuticals Inc
03/08/201814h00GlobeNewswire Inc.U.S. Centers for Medicare and Medicaid Services (CMS) Grants New Technology Add-On Payment for Portola Pharmaceuticals’ An...NASDAQ:PTLAPortola Pharmaceuticals Inc
02/08/201814h30GlobeNewswire Inc.Portola Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 201...NASDAQ:PTLAPortola Pharmaceuticals Inc
27/07/201814h24GlobeNewswire Inc.European CHMP Maintains Negative Opinion on Portola Pharmaceuticals’ Betrixaban Following AppealNASDAQ:PTLAPortola Pharmaceuticals Inc
06/07/201821h27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
06/07/201821h23Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTLAPortola Pharmaceuticals Inc
03/07/201814h30GlobeNewswire Inc.Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:PTLAPortola Pharmaceuticals Inc
25/06/201814h30GlobeNewswire Inc.Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical OperationsNASDAQ:PTLAPortola Pharmaceuticals Inc
11/06/201822h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
08/06/201823h23Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTLAPortola Pharmaceuticals Inc
06/06/201812h18Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
05/06/201822h30GlobeNewswire Inc.Portola Pharmaceuticals to Present at Two Upcoming Investor ConferencesNASDAQ:PTLAPortola Pharmaceuticals Inc
04/06/201822h30GlobeNewswire Inc.Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018NASDAQ:PTLAPortola Pharmaceuticals Inc
04/06/201814h30GlobeNewswire Inc.New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor C...NASDAQ:PTLAPortola Pharmaceuticals Inc
10/05/201822h58Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
09/05/201822h05GlobeNewswire Inc.Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
04/05/201803h49GlobeNewswire Inc.U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa InhibitorsNASDAQ:PTLAPortola Pharmaceuticals Inc
02/05/201815h33GlobeNewswire Inc.Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018NASDAQ:PTLAPortola Pharmaceuticals Inc
25/04/201819h06GlobeNewswire Inc.Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncolog...NASDAQ:PTLAPortola Pharmaceuticals Inc
24/04/201822h28Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
13/04/201812h07Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
23/03/201814h06GlobeNewswire Inc.Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban i...NASDAQ:PTLAPortola Pharmaceuticals Inc
12/03/201817h12GlobeNewswire Inc.Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent Andex...NASDAQ:PTLAPortola Pharmaceuticals Inc
12/03/201813h30GlobeNewswire Inc.Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General CounselNASDAQ:PTLAPortola Pharmaceuticals Inc
05/03/201822h10GlobeNewswire Inc.Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highli...NASDAQ:PTLAPortola Pharmaceuticals Inc
28/02/201822h05GlobeNewswire Inc.Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
20/02/201822h47GlobeNewswire Inc.Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and BetrixabanNASDAQ:PTLAPortola Pharmaceuticals Inc
15/02/201822h05GlobeNewswire Inc.Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesda...NASDAQ:PTLAPortola Pharmaceuticals Inc
14/02/201823h15Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201816h01Edgar (US Regulatory)Schedule 13gNASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA